Making a decision on treatment options for patients diagnosed with early-stage breast cancer is an important choice and one that should be made with the best information possible. EndoPredict® can help accurately determine an individual patient’s 10-year risk of recurrence to help physicians identify which patients may consider safely forgoing chemotherapy.
The Foresight® carrier screen can help determine whether you carry inherited health conditions that you might pass on to a child. Knowing this information before you get pregnant, or early in your pregnancy, can make a difference in your family’s well-being.
GeneSight® is a clinically proven test to enhance medication selection for healthcare providers, helping them get their patients on the right medications faster. Powered by CPGxTM, GeneSight is a proprietary combinatorial pharmacogenomics technology that analyzes how an individual’s genetic variations affect his or her response to medications and provides an actionable, easy to interpret report. GeneSight is used by healthcare providers to help patients that are affected by neuropsychiatric conditions including depression, anxiety, bipolar disorder, schizophrenia, ADHD, posttraumatic stress disorder (PTSD) and other behavioral health conditions, as well as chronic pain.
Myriad myRisk® Hereditary Cancer is a 35-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on eight primary cancer sites.
riskScore® is a clinically validated algorithm that predicts a women’s remaining 5-year and lifetime risk of developing breast cancer.
COLARIS® testing assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine/endometrial cancer by detecting disease-causing mutations in the MLH1, MSH2, MSH6 and PMS2 genes.
COLARIS AP ® testing assesses a person’s risk of developing hereditary colorectal polyps and cancer by detecting mutations in the APC and MYH genes.
Myriad myPath® Melanoma measures 23 genes for which expression patterns differ between malignant melanoma and benign nevi. These genes are involved in cell differentiation, cell signaling, and immune response signaling.
BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).1,2,3
myChoice® HRD is a tumor test that can be used to guide important PARP inhibitor treatment decisions. By testing for BRCA1/2 status and Genomic Instability Status, which evaluates three downstream biomarkers associated with homologous recombination deficiency (HRD), myChoice HRD is capable of identifying more appropriate patients for PARP inhibitors than other biomarker assays.
The PrequelTM prenatal screen is a non-invasive test that you can take as early as 10 weeks into your pregnancy to learn about your baby’s chance to have a chromosome condition like Down syndrome.
Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.
- Intended Use: BRACAnalysis CDx® is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.Results of the test are used as an aid in identifying breast and ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants, who are or may become eligible for treatment with Lynparza® (olaparib). Detection of deleterious or suspected deleterious germline BRCA variants by the BRACAnalysis CDx test in ovarian cancer patients is also associated with enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy. This assay is for professional use only and is to be performed only at 320 Wakara Way, Salt Lake City, UT 84108.
- For more detailed information about Lynparza and its safety and efficacy please go to lynparza.com
- For more detailed information about Zejula and its safety and efficacy please go to zejula.com
Lynparza is a registered trademark of the AstraZeneca group of companies, Zejula is a registered trademark of Tesaro, Inc.